What's Going On With BioCryst Pharmaceuticals Stock?
Portfolio Pulse from Erica Kollmann
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares rose after announcing preliminary unaudited Orladeyo net revenue of $89.9 million for Q4 and $325 million for full year 2023. The company expects 2024 global net revenue for Orladeyo to be between $380 million and $400 million. CEO Jon Stonehouse commented on the growth trajectory and the company's path to profitability. Needham analyst Serge Belanger reiterated a Buy rating and a $12 price target for BCRX, noting the potential for profitability by 2025 without additional capital.
January 08, 2024 | 4:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharmaceuticals' stock is trading higher due to positive preliminary revenue figures for Orladeyo and optimistic revenue projections for 2024. The company's CEO expressed confidence in achieving financial independence and profitability. Needham's reiteration of a Buy rating and $12 price target supports the positive sentiment.
The stock price is likely to rise in the short term due to the release of strong revenue figures and future revenue projections that suggest growth and profitability. The positive analyst rating from Needham further reinforces investor confidence in the company's financial outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100